9/17/2013 3:07:15 PM
by Richard Daverman, PhD
September 17, 2013 -- The Shanghai Institute of Materia Medica will collaborate with Servier, a French pharma, on China development of lucitanib, a clinical-stage anti-angiogenic cancer drug. SIMM will undertake research into biomarkers for the drug. The two companies plan to conduct China clinical trials of lucitanib in specific indications with the help of Haihe Pharmaceutical, a SIMM subsidiary. SIMM and Servier will own China rights to the drug jointly, though the China trial will be part of Servier’s larger effort to obtain global regulatory approval of lucitanib. More details....
Help employers find you! Check out all the jobs and post your resume.
comments powered by